GenMark Diagnostics (Nasdaq: GNMK) reported earnings on Aug. 7. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), GenMark Diagnostics beat expectations on revenues and exceeded expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share dropped.

Margins increased across the board.

Revenue details
GenMark Diagnostics reported revenue of $3.6 million. The three analysts polled by S&P Capital IQ predicted a top line of $3.3 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $.9 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at -$0.26. The three earnings estimates compiled by S&P Capital IQ averaged -$0.27 per share. GAAP EPS were -$0.26 for Q2 versus -$0.39 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 40.1%, 8,370 basis points better than the prior-year quarter. Operating margin was -154.5%, 47,980 basis points better than the prior-year quarter. Net margin was -155.0%, 46,430 basis points better than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $4.5 million. On the bottom line, the average EPS estimate is -$0.18.

Next year's average estimate for revenue is $15.7 million. The average EPS estimate is -$0.88.

Investor sentiment

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on GenMark Diagnostics is buy, with an average price target of $9.75.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.